

BIORANKINGS


ALTERNATIVE STATISTICS CALCULATED FROM GPC DATA

BioRankings predicted that GPC's Satraplatin would fail before the company's announcement

Clinical Trial

The SPARC trial, funded by GPC Biotech, studied satraplatin in hormone refractory prostate cancer. They filed an NDA for accelerated approval, but it was withdrawn based on vote by ODAC on July 24, 2007 that the FDA should wait for final survival analysis before deciding on approval.

Using the data from the overall survival curve (as shown), GPC focused on patients who survived twelve months. Based on this, they predicted a positive outcome.



BioRankings showed GPC's argument was flawed. By examining different possible mortality rates for the two study arms (refer to table) we were able to calculate p values that could be achieved in their ongoing trial. From this analysis, no p values reached statistical significance.

BioRankings Statistical Analyses

Mortality rate		# Dead	# Alive	P value
0%	Satraplatin	309	326	0.99
0%	Placebo	154	161	
30.4%	Satraplatin	362	273	0.41
20.2%	Placebo	170	145	
20.2%	Satraplatin	344	291	0.60
30.4%	Placebo	177	138	
30.4%	Satraplatin	362	273	0.24
50.0%	Placebo	193	122	

Conclusions

Our calculations showed conclusively that the SPARC trial would fail to achieve an overall survival improvement.

Three months later (October 2007) GPC and partners reported, as we predicted, that the trial did not achieve the endpoint of overall survival ($p=0.80$).



BIORANKINGS

William D. Shannon, PhD (314) 704-8725